Dr. Lazar Mandinov

Dr. Lazar Mandinov

Therapeutic Area Head, Cardiovascular

Parexel International

Dr. Mandinov is currently Therapeutic Area Head, Cardiovascular at Parexel International, one of the leading CROs in the world. He is providing scientific and strategic guidance to clients and internal stakeholders on clinical trial design, clinical drug development from pre-clinical to post marketing, and regulatory submissions.  He is also developing strategy for business growth in the CV field and is directly involved in the execution of numerous clinical trials. Prior to that, he was a Sr. Director Scientific Affairs at Edwards Lifesciences in Irvine, CA, leading the clinical and regulatory strategy for the transcatheter SAPIEN XT and SAPIEN 3 aortic valves and developing a robust publication strategy in a close collaboration with several KOLs. He was a CMO and VP Clinical at Mitralign Inc, developing a transcatheter treatment for functional mitral regurgitation, and a Medical Director at Boston Scientific in Natick, MA, leading the Taxus Liberte clinical program and supporting the IVUS and imaging department. With more than 15 years of experience in pharma, biotech and medical device industry Dr. Mandinov became an expert in clinical development (Phase I-IV trials), clinical and medical affairs, safety, and regulatory affairs.

Dr. Mandinov is board-certified in Internal Medicine and Cardiology. He completed his Internal Medicine training at the Medical University in Sofia, at the same time when he was attending the PhD Program. Dr. Lazar Mandinov completed Cardiology fellowship training at National Center for Cardiovascular Disease in Sofia with a focus on interventional cardiology and became Assistant Professor of Cardiology. He then joined the Interventional Cardiology team at the University Hospital Zurich and the University Hospital Bern, Switzerland for 6 years. He eventually joined Maine Medical Research Institute in Scarborough, ME where he headed several research projects involving the development of novel therapies for coronary restenosis and atherosclerosis.

Dr. Mandinov has an extensive expertise in coronary and structural heart interventions, CHF, heart transplantation, hypertension, PAH, coronary restenosis and stent thrombosis, cell biology, inflammation, and animal disease models. He published more than 150 peer-reviewed manuscripts, book chapters, and abstracts and was a recipient of research grants, and a winner of international and national awards.

Skip to content